6:10 PM
 | 
Mar 22, 2010
 |  BC Extra  |  Politics & Policy

FDA publishes IBS draft guidance

FDA issued draft guidance on the design of clinical trials for diarrhea- or constipation-predominant irritable bowel syndrome (IBS-D or IBS-C). The agency said the ideal primary endpoint for IBS trials is a patient-reported outcome (PRO) instrument that measures the clinically important signs and symptoms associated with each IBS...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >